Sign In
Buy MSA
$164.59
+1.32 (+0.81%)
At Close: Jun 03, 2026
Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress
06:00am, Monday, 28'th Apr 2025
DUBLIN , April 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of ampreloxetin
Bet on These 5 Top-Ranked Stocks With Rising P/E
08:40am, Monday, 21'st Apr 2025
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Carvana, Context Therapeutics Inc, Inovio Pharmaceuticals, ChargePoint and MSA Safety Inc.
All You Need to Know About MSA Safety (MSA) Rating Upgrade to Buy
01:00pm, Wednesday, 16'th Apr 2025
MSA Safety (MSA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MSA Safety Schedules First Quarter 2025 Earnings Conference Call
04:30pm, Tuesday, 15'th Apr 2025
PITTSBURGH , April 15, 2025 /PRNewswire/ -- MSA Safety Incorporated (NYSE: MSA), a global leader in the development of advanced safety products and solutions that protect people and facility infrastru
MSA Safety (MSA) Surges 8.1%: Is This an Indication of Further Gains?
08:45am, Thursday, 10'th Apr 2025
MSA Safety (MSA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r
The Best Gets Better: MSA Safety Announces Enhancements to its G1 SCBA Platform at FDIC 2025
08:15am, Wednesday, 09'th Apr 2025
Company Also Highlights Continuous Innovation with new Globe Turnout Jacket PITTSBURGH , April 9, 2025 /PRNewswire/ -- Innovation in the fire service is a continuous journey, where changing custome
BioArctic receives Orphan Drug Designation for exidavnemab the US
01:49pm, Monday, 17'th Mar 2025
STOCKHOLM , March 17, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designat
MSA Safety CFO Lee McChesney Resigns to Accept New Opportunity; Elyse Brody Appointed Interim CFO
04:45pm, Thursday, 13'th Mar 2025
PITTSBURGH , March 13, 2025 /PRNewswire/ -- MSA Safety Incorporated (NYSE: MSA) today announced it has accepted the resignation of its Chief Financial Officer, Lee B. McChesney, effective March 21,
MSA Safety Incorporated (MSA) Q4 2024 Earnings Call Transcript
11:07pm, Thursday, 13'th Feb 2025
MSA Safety Incorporated (NYSE:MSA ) Q4 2024 Earnings Conference Call February 13, 2025 10:00 AM ET Company Participants Larry De Maria - Executive Director of IR Steven Blanco - President and CEO Lee
MSA Safety (MSA) Tops Q4 Earnings Estimates
07:01pm, Wednesday, 12'th Feb 2025
MSA Safety (MSA) came out with quarterly earnings of $2.25 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.06 per share a year ago.
MSA Safety Announces Fourth Quarter and Full Year 2024 Results
04:30pm, Wednesday, 12'th Feb 2025
Fourth Quarter 2024 Highlights Achieved net sales of $500 million, a 1% GAAP increase and 2% organic(a) increase year-over-year Generated GAAP operating income of $118 million, or 23.5% of sales, and
MSA Safety Showcasing Automatic Leak Detection and Monitoring Expertise at AHR Expo
04:25pm, Thursday, 06'th Feb 2025
MSA to Feature FieldServer Gateways Designed to Enhance Network Protocol Connectivity PITTSBURGH , Feb. 6, 2025 /PRNewswire/ -- The spotlight on refrigerant leak detection, monitoring and reporting
MSA Safety Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call
04:45pm, Monday, 03'rd Feb 2025
PITTSBURGH , Feb. 3, 2025 /PRNewswire/ -- MSA Safety Incorporated (NYSE: MSA), a global leader in the development of advanced safety products and solutions that protect people and facility infrastruct
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
07:35am, Friday, 24'th Jan 2025
Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February 2025 ATH434-201 trial in early-stage MSA completed in November 20
2 Magnificent Dividend Kings Down 19% and 32% to Buy in 2025
06:38am, Saturday, 18'th Jan 2025
Today's Dividends Kings are a who's-who of the most successful dividend growth stocks of our time. This list consists of about 50 publicly traded companies that have increased their dividend payments
